GW572016 and Trastuzumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER2/Neu

NCT ID: NCT00085020

Last Updated: 2020-08-03

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 13 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2004-03-31
• Study Completion Date: 2005-02-28

Brief Summary

RATIONALE: GW572016 may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Monoclonal antibodies, such as trastuzumab, can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Giving GW572016 with trastuzumab may kill more tumor cells.

PURPOSE: This phase I trial is studying the side effects and best dose of GW572016 when given together with trastuzumab in treating patients with metastatic breast cancer that overexpresses HER2/neu.

Detailed Description

OBJECTIVES:

Primary

• Determine the optimally tolerated regimen of GW572016 when administered with trastuzumab (Herceptin^®) in patients with metastatic breast cancer that overexpresses HER2/neu.
• Determine the safety and tolerability of this regimen in these patients.

Secondary

• Determine the pharmacokinetic parameters of this regimen in these patients.
• Determine the clinical response in patients treated with this regimen.

OUTLINE: This is an open-label, multicenter, dose-escalation study of GW572016.

Patients receive oral GW572016 once daily on days 1-28 and trastuzumab (Herceptin^®) IV over 90 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Cohorts of 3-6 patients receive escalating doses of GW572016 until the optimally tolerated regimen (OTR) is determined. The OTR is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity. Once the OTR is determined, 10-18 additional patients are entered and treated at the OTR.

Patients are followed at 28 days.

PROJECTED ACCRUAL: A total of 3-35 patients will be accrued for this study.

Conditions

Breast Cancer

Study Design

• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Interventions

trastuzumab

Intervention Type: BIOLOGICAL

lapatinib ditosylate

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Histologically or cytologically confirmed breast cancer
• Metastatic disease
• Measurable or evaluable disease
• HER2/neu overexpression (2+ or 3+) confirmed by immunohistochemistry and/or HER2 gene amplification by fluorescence in situ hybridization
• Brain metastases treated by surgery and/or radiotherapy allowed provided the following criteria are met:

• Neurologic status stable 2 weeks after discontinuing dexamethasone
• No concurrent anticonvulsants that induce metabolism (e.g., phenytoin, carbamazepine, or phenobarbital)
• 18 and over
• Male or female
• Karnofsky 70-100%
• Life expectancy, At least 12 weeks
• Hematopoietic

• Absolute granulocyte count ≥ 1,500/mm^3
• Platelet count ≥ 100,000/mm^3
• Hemoglobin ≥ 9 g/dL
• AST and ALT ≤ 3 times upper limit of normal (ULN) (5 times ULN if patient has liver metastases)
• Bilirubin < 1.5 mg/dL
• Creatinine clearance > 30 mL/min
• Cardiovascular

• LVEF > 50%
• Negative pregnancy test
• Fertile patients must use effective contraception during and for 4 weeks after study participation
• Adequate venous access
• Able to swallow and retain oral medication
• Prior adjuvant/neoadjuvant chemotherapy allowed
• More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin.
• More than 4 weeks since prior radiotherapy
• More than 4 weeks since prior major surgery
• Recovered from all prior therapy
• More than 28 days since prior participation in another investigational study
• More than 28 days since prior investigational drugs

Exclusion Criteria

• extensive tumor, pleural effusions, or parenchymal masses) resulting in dyspnea at rest
• uncontrolled brain metastases or leptomeningeal disease
• prior myocardial infarction
• pre-existing cardiac dysfunction (e.g., congestive heart failure)
• clinically significant cardiac disease
• angina pectoris
• symptomatic intrinsic pulmonary disease (e.g., asthma or chronic obstructive pulmonary disease) resulting in dyspnea at rest
• pregnant or nursing
• active infection
• known hypersensitivity to Chinese Hamster Ovary cell proteins or any component of this product
• known immediate or delayed hypersensitivity reaction or idiosyncrasy to products of similar chemical composition as study drug
• known contraindications to trastuzumab (Herceptin^®)
• malabsorption syndrome
• disease significantly affecting gastrointestinal function
• psychiatric disorder that would preclude study compliance
• other serious illness or condition
• concurrent biologic therapy
• prior cumulative dose of doxorubicin > 400 mg/m^2 (including liposomal doxorubicin)
• concurrent hormonal therapy*
• concurrent glucocorticoids
• concurrent radiotherapy
• prior major resection of the stomach or small bowel that could affect absorption of GW572016
• concurrent cytotoxic therapy
• other concurrent anticancer therapy
• other concurrent investigational drugs during and for 28 days after study treatment
• concurrent administration of any of the following medications or substances:
• Antibiotics

• Clarithromycin
• Erythromycin
• Troleandomycin
• Ciprofloxacin
• Rifampin
• Norfloxacin
• Rifabutin
• HIV antivirals

• Delaviridine
• Indinavir
• Nelfinavir
• Ritonavir
• Saquinavir
• Efavirenz
• Nevirapine
• Amprenavir
• Lopinavir
• Anticonvulsants

• Phenytoin
• Carbamazepine
• Phenobarbital
• Antidepressants

• Fluoxetine
• Nefazodone
• Fluvoxamine
• Antifungals

• Itraconazole
• Ketoconazole
• Fluconazole
• Voriconazole
• Antacids (within 1 hour before and after study drug administration)
• Cimetidine
• Amiodarone
• Diltiazem
• Pioglitazone
• Hypericum perforatum (St. John's wort)
• Grapefruit or grapefruit juice
• Rifabutin
• Diethyldithiocarbamate
• Gestodene
• Mifepristone
• Modafinil

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

GlaxoSmithKline

INDUSTRY

Sponsor Role: collaborator

Jonsson Comprehensive Cancer Center

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Mark D. Pegram, MD

Role: PRINCIPAL_INVESTIGATOR

Jonsson Comprehensive Cancer Center

Locations

Jonsson Comprehensive Cancer Center, UCLA

Los Angeles, California, United States

Countries

United States

References

Storniolo AM, Burris HA III, Overmoyer B, et al.: A phase I, open-label study of the safety, tolerability and pharmacokinetics of lapatinib (GW572016) in combination with trastuzumab. [Abstract] Breast Cancer Research and Treatment 94 (Suppl 1): A-1040, 2005.

Reference Type: RESULT

Burris III HA, Storniolo AM, Overmoyer EA, et al.: A phase I, open-label study of the safety, tolerability and pharmacokinetics of lapatinib (GW572016) in combination with trastuzumab. [Abstract] Breast Cancer Res Treat 88 (1): A-3043, 2004.

Reference Type: RESULT

Other Identifiers

UCLA-0305039

Identifier Type: -

Identifier Source: secondary_id

GSK-EGF10023

Identifier Type: -

Identifier Source: secondary_id

CDR0000367118

Identifier Type: -

Identifier Source: org_study_id